Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — FY2012 Earnings Presentation

13 slides from Questcor Pharmaceuticals's earnings presentation, Mar 4, 2013

  1. Slide 1: Fourth Quarter and Full Year 2012 Conference Call

    NASDAQ: QCOR Fourth Quarter and Full Year 2012 Conference Call

  2. Slide 2: Conference Call Logistics

    Conference Call Logistics Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 95427085 By webcast: At Questcor’s in

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc

  4. Slide 4: Fourth Quarter Financial Results

    Fourth Quarter Financial Results 6,330 vials shipped, up 88% YOY $160.5M in net sales, up 113% YOY $1.03 GAAP EPS (diluted), up 115% YOY $1.09 Non-GAAP EPS (diluted), up 132% YOY Note: See Reconciliation of Non-GAAP Adjusted Financial Disclosure slide 12.

  5. Slide 5: Full Year 2012 Financial Results

    Full Year 2012 Financial Results 20,741 vials shipped, up 94% YOY $509.3M in net sales, up 133% YOY $3.14 GAAP EPS (diluted), up 160% YOY $3.33 Non-GAAP EPS (diluted), up 162% YOY Note: Note: See Reconciliation of Non-GAAP Adjusted Financial Disclosure slide 12.

  6. Slide 6: Estimated Allocation of Acthar Net Sales

    Estimated Allocation of Acthar Net Sales Infantile Spasms ~10% DM/PM ~5% Other 3% Nephrotic Syndrome 44-48% MS Relapse 34-38% Note: Questcor sells Acthar to a distributor and does not have complete data with respect to end-use; allocation based on internal estimates (Q4 2012).

  7. Slide 7: Stable Reimbursement Environment

    Stable Reimbursement Environment MDs typically reserve Acthar for when another FDA-approved treatment alternative is needed, usually after first-line therapy – Serious, difficult-to-treat medical conditions Coverage decisions are determined on a case-by-case basis, considering patient condition, dis

  8. Slide 8: The Emerging Science Behind Acthar

    The Emerging Science Behind Acthar Preclinical and Clinical Studies Understanding the biological properties of Acthar – Effect on specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory effects Further research related to on-label indications – Lupus – Idiopathic M

  9. Slide 9: Q4-2012 Financial Results

    Q4-2012 Financial Results Record Net Sales (up 113%) and GAAP EPS (up 115%) Q4 – 2012 Q4 – 2011 Net Sales ($M) $160.5 $75.5 Gross Profit ($M) $151.4 $71.5 Operating Income ($M) $94.8 $42.7 Fully Diluted, GAAP EPS $1.03 $0.48 Fully Diluted, Non-GAAP EPS $1.09 $0.47 Cash flow from operations (YTD $M)

  10. Slide 10: Increasing Support of Questcor-Sponsored and Independent Research Projects

    Increasing Support of Questcor-Sponsored and Independent Research Projects R&D Spending Clinical & Preclinical Studies $ Millions 40 35 30 25 20 15 10 5 0 2007 2008 2009 2010 2011 2012 80 70 60 50 40 30 20 10 0 2007 2008 2009 2010 2011 2012 4.8 10.6 10.9 9.7 16.8 34.3 0 2 33 34 20

  11. Slide 11: Strong Net Sales Growth

    Strong Net Sales Growth 180 160 140 120 100 80 60 40 20— Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-11 Q3-11 Q4-11 Q1-12 Q2-12 Q3-12 Q4-12 Net Sales per Quarter Millions ($)

  12. Slide 12: Reconciliation of Non-GAAP Adjusted Financial Disclosure

    Reconciliation of Non-GAAP Adjusted Financial Disclosure Three Months Ended Three Months Ended Twelve Months Ended Twelve Months Ended 12/31/12 12/31/11 12/31/12 12/31/11 Adjusted net income per share—basic $ 1.13 $ 0.50 $ 3.48 $ 1.34 Share-based compensation expense (1)(0.06)(0.02)(0.17)(0.08) Depr

  13. Slide 13: Fourth Quarter and Full Year 2012 Conference Call

    NASDAQ: QCOR Fourth Quarter and Full Year 2012 Conference Call

Questcor Pharmaceuticals — FY2012 Earnings Presentation on 6ix